Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Centre hospitalier de l'Université de Montréal (CHUM)
UMC Utrecht
University of Colorado, Denver
City of Hope Medical Center
University of Nebraska
Natera, Inc.
Novartis
Var2 Pharmaceuticals
Massive Bio, Inc.
UNC Lineberger Comprehensive Cancer Center
Washington University School of Medicine
A2 Biotherapeutics Inc.
Sahlgrenska University Hospital
City of Hope Medical Center
Guardant Health, Inc.
University of California, San Francisco
ModeX Therapeutics, An OPKO Health Company
Columbia University
Tempus AI
Instituto de Investigacion Sanitaria La Fe
Stanford University
Rutgers, The State University of New Jersey
Stanford University
Aalborg University Hospital
Mansoura University
Taproot Health
Northwestern University
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
DxTerity Diagnostics
Washington University School of Medicine
Sun Yat-sen University
The Griffin Institute
Institut de cancérologie Strasbourg Europe
Charite University, Berlin, Germany
Corvus Pharmaceuticals, Inc.
Sunnybrook Health Sciences Centre
Charite University, Berlin, Germany
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
M.D. Anderson Cancer Center
Klus Pharma Inc.
Eastern Cooperative Oncology Group
Eastern Cooperative Oncology Group
Weprom
MacroGenics
RenJi Hospital
Wake Forest University Health Sciences
Jerome Canady Research Institute for Advanced Biological & Technological Sciences
Institut Bergonié
Abramson Cancer Center at Penn Medicine